AOD-9604
Case StudyCommunity knowledge about AOD-9604 captures what aggregated dosing diaries and self-reports reveal about real-world use. A modified human growth hormone fragment studied for fat metabolism without the growth-promoting side effects of full GH. The patterns that emerge — dose ranges that produce response without diminishing returns, stack pairings that work and don't, sourcing tier that matches subjective response — are the practical wisdom not always captured in clinical literature.
Key Takeaways
Community lens: aggregated reports on AOD-9604 converge on incremental rather than dramatic effects over 4-8 weeks. Mechanism: Mimics the C-terminal of human growth hormone (residues 176-191) to stimulate lipolysis and inhibit lipogenesis via β3-adrenergic-like signalling, without engaging the GH receptor or driving IGF-1 elevation. Reported non-response rate: 15-25% of users describe absent or partial response at 300-500 mcg 1x daily am dosing. Community dose-range convergence: research-dose range produces modal response; substantial upward adjustment produces diminishing returns. Community-favoured stack partners: BPC-157, TB-500, Ipamorelin.
Mimics the C-terminal of human growth hormone (residues 176-191) to stimulate lipolysis and inhibit lipogenesis via β3-adrenergic-like signalling, without engaging the GH receptor or driving IGF-1 elevation. The community translation of this mechanism: what users report at the modal dose, the diary patterns that emerge across many reports, the stack combinations the community converges on, and the honest non-response rate that experienced users discuss but novice users often miss.
Common dosing diary patterns
User dosing diaries converge on 300-500 mcg as the standard, with experienced users sometimes adjusting upward by 25–50% and reporting diminishing returns thereafter. The diary patterns also show that subcutaneous administration is the dominant route, and that consistency matters more than absolute dose.
What works and what doesn't
Honesty about non-response is one of the more useful contributions of community reporting. Roughly 15–25% of users report that AOD-9604 did not produce the expected effect for their specific use case. The most-cited reasons: dose timing relative to food, vendor quality issues, expectations calibrated to dramatic stories rather than the actual modest profile, and stacking complexity that masked the individual contribution.
Stacking patterns and community wisdom
The most-reported AOD-9604 stack combinations rotate through hGH fragment 176-191, AOD9604 and the canonical pairings appropriate to its mechanism. Community convergence on these patterns is one of the most useful signals for new users — not because the community is always right, but because the well-tolerated combinations have been filtered over many cycles.
For what worked, community first-cycle reports on AOD-9604 tend to undersell the response, while second-cycle reports tend to oversell. The honest middle is what experienced users describe — modest, consistent, and worth the protocol effort for users with baseline-appropriate indications.
Community dosing diaries for AOD-9604 in onset & duration converge on consistent dosing patterns. The shared wisdom is more useful than any individual report — not because the community is always right but because consistent patterns across many users filter idiosyncratic experiences.
Subjective Effect Timeline is one of the more-reported community use cases for AOD-9604. The aggregate experience pattern: most users report incremental benefit within 4–8 weeks, a minority report no response, and dramatic responses are rare. Setting expectations to the modal experience improves user satisfaction.
For side effect reports, community first-cycle reports on AOD-9604 tend to undersell the response, while second-cycle reports tend to oversell. The honest middle is what experienced users describe — modest, consistent, and worth the protocol effort for users with baseline-appropriate indications.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 300-500 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 180-500 mcg | 4–6 weeks initial cycle |
| Case Study focus | SubQ | 300-500 mcg | 1x daily AM |
| Maintenance phase | SubQ | 210-500 mcg | Ongoing with periodic pauses |
Dose timing for AOD-9604 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.
AOD-9604 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the experienced peptide community.
- AOD-9604 + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with AOD-9604's mechanism in first-person / case studies protocols.
- AOD-9604 + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with AOD-9604's mechanism in first-person / case studies protocols.
- AOD-9604 + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with AOD-9604's mechanism in first-person / case studies protocols.
- AOD-9604 + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with AOD-9604's mechanism in first-person / case studies protocols.
No significant elevation of IGF-1, glucose, or insulin in trials. Generally well tolerated. Pregnancy/lactation: avoid (no data).
Lens-specific safety considerations for first-person / case studies use of AOD-9604: No significant elevation of IGF-1, glucose, or insulin in trials. Generally well tolerated. Pregnancy/lactation: avoid (no data). Additional first-person / case studies monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| AOD-9604 | GH fragment | ~30 min IV; longer SubQ | Case Study |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
Common mistakes new users make?
Is AOD-9604 a good first peptide?
Side effects users actually report?
Best practice for storage and travel?
How does AOD-9604's half-life affect dosing?
What is the regulatory status of AOD-9604?
Start a AOD-9604 Protocol
Alukard provides physician-supervised protocols with GMP-certified AOD-9604 and GMP-certified compounds dispensed with personalised dosing protocols.
Get ProtocolQuick Facts
- Molecular weight
- 1815.1 Da
- Sequence length
- 16 aa
- Half-life
- ~30 min IV; longer SubQ
- WADA
- Not on prohibited list (verify annually)
- FDA
- Unapproved (Research Only)
- Research
- Phase IIb completed; not commercialised
Stack Partners
All first-person / case studies applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for AOD-9604 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your First-Person / Case Studies Protocol for AOD-9604
Alukard provides physician-supervised protocols with GMP-certified compounds dispensed with personalised dosing protocols.
HIPAA Compliant · GMP Certified · Physician Supervised